Ascentage Pharma Group International (AAPG) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong financial performance with robust enrollment in clinical trials and significant commercial growth opportunities for key products in China. Positive market strategies, such as NRDL coverage and partnerships with Takeda, support growth. The Q&A section highlights analysts' positive sentiment, despite some unclear management responses. Overall, the combination of strong clinical data, market expansion, and strategic partnerships suggests a positive impact on stock price.
Key Financial Performance
Total Revenue $82.1 million, a 90% year-over-year increase. This growth was driven by the Dual-Engine commercialization strategy centered on Olverembatinib and Lisaftoclax.
Olverembatinib Sales $62.2 million, an 81% year-over-year growth. This was attributed to the first full year of NRDL inclusion, hospital and DTP market penetration, which drove increased volume uptake.
Lisaftoclax Sales $10.1 million in the first 5 months post-approval. This was due to the established commercial infrastructure built to scale ahead of approval, enabling rapid market penetration.
R&D Expenses $163 million, a 20.1% year-over-year increase from $130 million. This increase was tied to advancing ongoing global pivotal studies.
Sales and Distribution (S&D) Expenses $51 million, an increase from $27 million in 2024. This was primarily driven by sales force expansion ahead of the commercial launch of Lisaftoclax.
Year-End Cash Balance $353.2 million, compared to $172.8 million in 2024. This increase was due to product sales and two successful financings in 2025, raising $322.6 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Lisaftoclax approval: Approved as a global first single-agent Bcl-2 inhibitor after BTK treatment in CLL and SLL. Achieved $10.1 million in sales within the first 5 months of launch.
Olverembatinib: Sales reached $62.2 million, representing 81% year-over-year growth. Approved for full NRDL coverage in China and demonstrated strong efficacy in multiple trials.
APG-3288: FDA and CDE IND clearance for novel BTK degrader. Trials ongoing in the U.S. and China.
Dual-Engine commercialization strategy: Transitioned to self-sustaining revenue model with 100% sales from commercial products. Expanded commercial team to 270 staff, covering 1,500 hospitals and 800 DTP pharmacies.
Global market expansion: Advanced global registrational trials for Lisaftoclax and Olverembatinib, with FDA, EMA, and CDE clearances. Expanded trials to 20 countries.
Revenue growth: Achieved total revenue of $82.1 million, a 90% year-over-year increase.
Cash balance: Year-end cash balance of $353.2 million, supported by $322.6 million raised through IPO and follow-on offering.
R&D investment: Increased R&D expenses by 20.1% to $163 million to support global pivotal studies.
Strategic positioning: Positioned as a global leader in hematology/oncology with a focus on innovative therapies.
Pipeline development: Focused on advancing 7 novel compounds, including Lisaftoclax, Olverembatinib, and APG-3288, targeting hematological malignancies and anemia.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approvals and Clinical Trials: The company faces risks in advancing enrollment for global Phase III registrational trials (GLORA-4, POLARIS-1, POLARIS-2) and achieving timely regulatory approvals. Delays in enrollment or regulatory hurdles could impact the timeline for filing NDAs in 2027.
Commercialization Challenges: Despite strong initial sales of Lisaftoclax and Olverembatinib, the company must expand market penetration to Tier 1 hospitals and pharmacies. Failure to achieve broader NRDL coverage for Lisaftoclax in China by 2026 could limit revenue growth.
Financial Sustainability: The company has a high reliance on revenue from two products, Lisaftoclax and Olverembatinib. Any market or competitive disruptions affecting these products could significantly impact financial performance.
R&D and Pipeline Risks: The company is heavily invested in advancing its late-stage pipeline, including novel compounds like the BTK degrader APG-3288 and EED inhibitor APG-5918. Failure in clinical trials or inability to demonstrate safety and efficacy could jeopardize future growth.
Operational and Cost Management: The company has increased R&D and sales/distribution expenses significantly. Inefficient cost management or failure to generate sufficient revenue to offset these expenses could strain financial resources.
Market Competition: The company faces competition from existing therapies like venetoclax and ponatinib. Superior safety and efficacy claims for Lisaftoclax and Olverembatinib must be validated to maintain competitive advantage.
Global Expansion Risks: Efforts to establish a global presence in hematology/oncology markets require significant investment and operational execution. Failure to achieve global branding and market penetration could hinder strategic objectives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Enrollment and NDA Filing: The company aims to complete enrollment for GLORA and GLORA-4 registrational trials, as well as POLARIS-1 and POLARIS-2 trials, with plans to file NDAs in 2027.
Sales Growth: Focus on driving sales growth for Olverembatinib and Lisaftoclax by expanding reach to Tier 1 hospitals and pharmacies. Lisaftoclax is targeted for NRDL coverage in China by 2026.
Pipeline Development: Plans to advance the global Phase I study of BTK degrader APG-3288 and EED inhibitor APG-5918 in oncology and anemia. Other active compounds will also progress in clinical studies in the U.S. and China.
Commercial Strategy: The company will continue leveraging its dual-engine commercialization strategy to sustain revenue growth and support R&D programs.
Financial Outlook: Maintains a cash runway through 2027, supported by product sales and successful financings in 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide an update on the enrollment status for the GLORA-4 study in MDS and the POLARIS-1 study in Ph+ ALL?
A:The GLORA-4 Phase III trial for high-risk MDS has received clearance from regulatory agencies in nearly 20 countries, including the FDA, EMA, and CDE. It is the only Phase III registrational trial globally for high-risk MDS. The POLARIS-1 study for Ph+ ALL showed a 64% MRD-negative CR rate at 3 months, nearly double the rate of ponatinib. Both trials are progressing well with strong enrollment and support from healthcare providers. The company aims to complete enrollment and file an NDA by 2027.
Q:What are the commercial growth opportunities for Olverembatinib and Lisaftoclax in China this year?
A:Key drivers include broader reimbursement support for Olverembatinib after NRDL inclusion, expanded hospital and pharmacy access, and the launch of Lisaftoclax, which generated over RMB 70 million in sales in its first 5 months. The commercial team has tripled in size, covering over 1,500 hospitals nationwide. These factors are expected to drive growth.
Q:How does the BTK Degrader differentiate from others in the market, and what are the expectations for the Phase I study?
A:The BTK Degrader shows better selectivity and potency based on preclinical data. It addresses issues with BTK inhibitors, including mutations, and has potential applications in oncology and autoimmune diseases. The Phase I study will focus on safety, tolerability, PK, and efficacy signals, with plans to move quickly into single-agent indications and combinations with Bcl-2 inhibitors.
Q:What is the market share of Olverembatinib in China compared to Asciminib and Ponatinib, and what growth is expected in 2026?
A:Olverembatinib benefits from NRDL coverage, significantly reducing patient costs by 70-90%. Asciminib and Ponatinib, approved last year, lack NRDL coverage, limiting their affordability and use. Olverembatinib's market share is expected to grow in 2026 due to continued NRDL support and expansion into Ph+ ALL.
Q:How does Olverembatinib fit into the emerging CML treatment landscape in the U.S., and what global pivotal trial data can be expected in 2027?
A:Olverembatinib is positioned as a strong competitor in the CML market, which has a global annual sales potential of $14 billion. The company has partnered with Takeda for global commercialization. Data from the GLORA-4, POLARIS-1, and POLARIS-2 trials are expected in 2027, with plans to file NDAs for these indications.
Q:How does Olverembatinib compare to TERN-701, and what is the progress on expanding into second-line or earlier lines in CML?
A:Olverembatinib has broader and more potent activity, including against T315I mutations, and long-term safety data. It is positioned as the first choice for second-line treatment. The company is conducting trials for second-line CML and has approval for near second-line use in China.
Q:What are the dynamics for Lisaftoclax's uptake in 2026 given the approval of BeOne's Bcl-2 inhibitor?
A:Lisaftoclax launched 6 months ahead of BeOne's Sonrotoclax in China and has advantages such as a simpler dosing regimen, better safety profile, and fewer drug-drug interactions. The company is confident in Lisaftoclax's competitive position and plans to expand its indications and global trials.
Q:What is the target number of hospitals for formulary inclusion in China, and are there plans to explore non-oncology indications for the BTK Degrader?
A:The target is to cover 2,000 hospitals, with 1,500 already covered. The BTK Degrader has potential applications in non-oncology areas like autoimmune and CNS diseases, supported by preclinical data.
Q:How does the company view the CLL market's shift towards all-oral, time-limited therapies, and how does this align with their BTK Degrader and Lisaftoclax strategy?
A:The company sees a trend towards fixed-duration therapies for CLL, especially for younger patients. The combination of the BTK Degrader and Lisaftoclax offers potential for fixed-duration treatment with long-term PFS and possibly clinical cure in some cases. This strategy aligns with market trends and patient needs.
Q:What are the conditions for Takeda to exercise its option agreement for Olverembatinib, and is the company open to partnering Lisaftoclax?
A:Takeda's option is contingent on resolving antitrust issues, likely after ponatinib's patent expiration. The company is open to partnerships for Lisaftoclax while also preparing for U.S. commercialization.
Q:What are the market dynamics for allosteric inhibitors like Asciminib in the CML space, and how does Olverembatinib compare?
A:Asciminib has over $1 billion in annual sales but is less effective against T315I mutations and lacks strong activity in Ph+ ALL. Olverembatinib has broader efficacy, long-term safety data, and is positioned as the best second-line treatment option.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the specific growth rate expectations for Olverembatinib in 2026, providing general comments on NRDL support and market expansion instead. Additionally, they did not provide clear details on Takeda's timeline for exercising its option agreement for Olverembatinib.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ABL inhibitor
ASH
BCR ABL
BTK
Bcl inhibitor
CLL SLL
CML
China
Dr
EMA CDE
FDA EMA
GLORA
III trial
Lisaftoclax Bcl
MDS
NRDL
Phase III
RD
USD
agent
approval
cash
clearance
combination
coverage
degrader
drug
end
hospital
line
patient
product
rate
risk
sale
study
treatment
AAPG Transcript
Ascentage Pharma Group International (AAPG) Q4 2025 Earnings Call Transcript
Positive3-26
The earnings call summary indicates strong financial performance with robust enrollment in clinical trials and significant commercial growth opportunities for key products in China. Positive market strategies, such as NRDL coverage and partnerships with Takeda, support growth. The Q&A section highlights analysts' positive sentiment, despite some unclear management responses. Overall, the combination of strong clinical data, market expansion, and strategic partnerships suggests a positive impact on stock price.
Ascentage Pharma Group International (AAPG) Presents At Citi's Biopharma Back To School Conference Transcript
Neutral9-3
AAPG Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
